AED Treatment through Different Ages: As Our Brains Change, Should Our Drug Choices Also?: AED Treatment Through Different Ages

Epilepsy Currents

Volumn 12, Issue 4_suppl, 2012, Pages 22-27

  French, Jacqueline A ^a   Staley, Brigid A ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84883013857     PISSN: 15357597     EISSN: 15357511     Source Type: Journal    
DOI: 10.5698/1535-7511-12.4s.22     Document Type: Review

References (35)

1. Ikonomidou C, Turski L. Antiepileptic drugs and brain development. Epilepsy Res 2010; 88: 11–22.
2. Jensen FE. Developmental factors in the pathogenesis of neonatal seizures. J Pediatr Neurol 2009; 7: 5–12.
3. Carmo KB, Barr P. Drug treatment of neonatal seizures by neonatologists and paediatric neurologists. J Paediatr Child Health 2005; 41: 313–316.
4. Painter MJ, Scher MS, Stein AD, et al. Phenobarbital compared with phenytoin for the treatment of neonatal seizures. New Engl J Med 1999; 341: 485–489.
5. Silverstein FS, Ferriero DM. Off-label use of antiepileptic drugs for the treatment of neonatal seizures. Pediatr Neurol 2008; 39: 77–79.
6. Fogarasi A, Tuxhorn I, Janszky J, et al. Age-dependent seizure semiology in temporal lobe epilepsy. Epilepsia 2007; 48: 1697–1702.
7. Palop JJ, Mucke L. Epilepsy and cognitive impairments in Alzheimer disease. Arch Neurol 2009; 66: 435–440.
8. Olafsson E, Ludvigsson P, Gudmundsson G, Hesdorffer D, Kjartansson O, Hauser WA. Incidence of unprovoked seizures and epilepsy in Iceland and assessment of the epilepsy syndrome classification: A prospective study. Lancet Neurol 2005; 4: 627–634.
9. Holmes GL, Khazipov R, Ben-Ari Y. New concepts in neonatal seizures. Neuroreport 2002; 13: A3–8.
10. Leppik IE, Kelly KM, deToledo-Morrell L, et al. Basic research in epilepsy and aging. Epilepsy Res 2006; 68(suppl): S21–S37.
11. Hancock E, Osborne JP. Vigabatrin in the treatment of infantile spasms in tuberous sclerosis: Literature review. J Child Neurol 1999; 14: 71–74.
12. French JA, Kanner AM, Bautista J, et al. Efficacy and tolerability of the new antiepileptic drugs II: Treatment of refractory epilepsy. Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2004; 62: 1261–1273.
13. French JA, Kanner AM, Bautista J, et al. Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new onset epilepsy. Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2004; 62: 1252–1260.
14. European Medicines Agency. Guideline on clinical investigation of medicinal products in the treatment of epileptic disorders. EMA Web site. http://www.ema.europa.eu/pdfs/human/ewp/056698enrev2.pdf. Accessed Month day, year.
15. Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: An unblinded randomised controlled trial. Lancet 2007; 369: 1000–1015.
16. Hunt S, Russell A, Smithson WH, et al. Topiramate in pregnancy: Preliminary experience from the UK Epilepsy and Pregnancy Register. Neurology 2008; 71: 272–276.
17. Tomson T, Battino D. Teratogenic effects of antiepileptic medications. Neurol Clin 2009; 27: 993–1002.
18. Cornejo BJ, Mesches MH, Coultrap S, Browning MD, Benke TA. A single episode of neonatal seizures permanently alters glutamatergic synapses. Ann Neurol 2007; 61: 411–426.
19. Holmes GL, Ben-Ari Y. Seizures in the developing brain: Perhaps not so benign after all. Neuron 1998; 21: 1231–1234.
20. Zeber JE, Copeland LA, Pugh MJ. Variation in antiepileptic drug adherence among older patients with new-onset epilepsy. Annals Pharmacother 2010; 44: 1896–1904.
21. Gilman JT, Duchowny M, Campo AE. Pharmacokinetic considerations in the treatment of childhood epilepsy. Paediatr Drugs 2003; 5: 267–277.
22. Pennell PB, Peng L, Newport DJ, et al. Lamotrigine in pregnancy: Clearance, therapeutic drug monitoring, and seizure frequency. Neurology 2008; 70: 2130–2136.
23. Harden CL, Pennell PB, Koppel BS, et al. Practice parameter update: Management issues for women with epilepsy—focus on pregnancy (an evidence-based review): Vitamin K, folic acid, blood levels, and breastfeeding. Report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society. Neurology 2009; 73: 142–149.
24. Perucca E, Berlowitz D, Birnbaum A, et al. Pharmacological and clinical aspects of antiepileptic drug use in the elderly. Epilepsy Res 2006; 68(suppl): S49–S63.
25. Perucca E, Grimaldi R, Gatti G, Pirracchio S, Crema F, Frigo GM. Pharmacokinetics of valproic acid in the elderly. British J Clin Pharm 1984; 17: 665–669.
26. Perucca E. Plasma protein binding of phenytoin in health and disease: Relevance to therapeutic drug monitoring. Ther Drug Monit 1980; 2: 331–344.
27. Birnbaum AK, Ahn JE, Brundage RC, Hardie NA, Conway JM, Leppik IE. Population pharmacokinetics of valproic acid concentrations in elderly nursing home residents. Ther Drug Monit 2007; 29: 571–575.
28. Birnbaum A, Hardie NA, Leppik IE, et al. Variability of total phenytoin serum concentrations within elderly nursing home residents. Neurology 2003; 60: 555–559.
29. Brodie MJ, Elder AT, Kwan P. Epilepsy in later life. Lancet Neurol 2009; 8: 1019–1030.
30. Pellock JM. Felbamate. Epilepsia 1999; 40(suppl): S57–S62.
31. Sankar R. Initial treatment of epilepsy with antiepileptic drugs: Pediatric issues. Neurology 2004; 63: S30–S39.
32. Camposano SE, Major P, Halpern E, Thiele EA. Vigabatrin in the treatment of childhood epilepsy: A retrospective chart review of efficacy and safety profile. Epilepsia 2008; 49: 1186–1191.
33. Nordli DR Jr. Special needs of the adolescent with epilepsy. Epilepsia 2001; 42(suppl): 10–17.
34. Klein A. Antiepileptic drugs and breastfeeding: Do we tell women “no”? Neurology 2010; 75: 1948–1949.
35. Mintzer S, Skidmore CT, Abidin CJ, et al. Effects of antiepileptic drugs on lipids, homocysteine, and C-reactive protein. Ann Neurol 2009; 65: 448–456.